Other Pharmaceuticals - Uganda

Uganda

The Other Pharmaceuticals market in Uganda is forecasted to achieve a revenue of UGX US$111.00m by the year 2024.
It is expected that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of 3.82%, leading to a market volume of UGX US$133.90m by 2029.
In terms of global comparison, United States is projected to generate the highest revenue of US$260.50bn in 2024.
Uganda's other pharmaceutical market is experiencing a surge in demand for traditional herbal remedies.

Key regions: China, Europe, Australia, United States, Germany

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Pharmaceuticals market in Uganda has shown significant growth in recent years.

Customer preferences: Customers in Uganda prefer affordable and accessible healthcare products. As a result, the demand for generic drugs has increased in the Other Pharmaceuticals market. Additionally, the preference for natural and herbal remedies has also contributed to the growth of this market.

Trends in the market: One of the major trends in the Other Pharmaceuticals market in Uganda is the increasing investment in research and development by pharmaceutical companies. This has led to the introduction of new and innovative products in the market. Another trend is the growing adoption of e-commerce platforms by pharmaceutical companies to improve their distribution channels and reach a wider customer base.

Local special circumstances: Uganda has a high burden of infectious diseases such as malaria, HIV/AIDS, and tuberculosis. This has led to a high demand for pharmaceutical products to treat these diseases. Additionally, the government's efforts to improve healthcare infrastructure and increase access to healthcare services have also contributed to the growth of the Other Pharmaceuticals market in Uganda.

Underlying macroeconomic factors: The Ugandan economy has been growing steadily in recent years, with a focus on diversifying the economy and increasing investment in key sectors such as healthcare. This has created a conducive environment for the growth of the Other Pharmaceuticals market. Additionally, the government's efforts to improve the business environment and attract foreign investment have also contributed to the growth of this market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.